trending Market Intelligence /marketintelligence/en/news-insights/trending/UOvd-OHxImg7llEtRcBqCw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ardian agrees to sell Riemser to Spanish pharmaceutical company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ardian agrees to sell Riemser to Spanish pharmaceutical company

Private equity firm Ardian agreed to sell all the shares of Riemser Pharma GmbH to Barcelona-based Esteve Pharmaceuticals SA.

Financial details of the transaction were not disclosed.

Riemser, headquartered in Greifswald and Berlin in Germany, provides specialty pharmaceuticals in human medicine. The company has subsidiaries in Great Britain, France and Spain with an international distribution network in more than 50 countries.

Ardian acquired Riemser in 2012 and refocused the company on its core business of specialty pharmaceuticals. Riemser's product portfolio consists of prescription drugs for the treatment of serious diseases in oncology, neurology, infectiology, as well as niche indications in cardiovascular medicine and dermatology, among others.

The closing of the transaction is subject to antitrust approval and is expected in the first quarter of 2020.